89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
Company profile
Ticker
ETNB
Exchange
Website
CEO
Rohan Palekar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
89Bio Ltd. • 89bio Management, Inc. • UAB 89bio Lithuania, a private limited liability company ...
IRS number
831114349
ETNB stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
8-K
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
17 Apr 24
8-K
Entry into a Material Definitive Agreement
10 Apr 24
S-8
Registration of securities for employees
7 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
10-K
2023 FY
Annual report
1 Mar 24
8-K
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
29 Feb 24
8-K
Entry into a Material Definitive Agreement
8 Dec 23
424B5
Prospectus supplement for primary offering
8 Dec 23
Latest ownership filings
4
Peter Kolchinsky
15 Apr 24
4
ROHAN PALEKAR
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
6 Mar 24
4
Peter Kolchinsky
6 Mar 24
4
ROHAN PALEKAR
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Ryan Martins
23 Feb 24
4
ROHAN PALEKAR
23 Feb 24
4
Quoc Le-Nguyen
23 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 251.93 mm | 251.93 mm | 251.93 mm | 251.93 mm | 251.93 mm | 251.93 mm |
Cash burn (monthly) | (no burn) | (no burn) | 13.12 mm | 11.31 mm | 10.12 mm | 10.17 mm |
Cash used (since last report) | n/a | n/a | 87.27 mm | 75.24 mm | 67.35 mm | 67.65 mm |
Cash remaining | n/a | n/a | 164.65 mm | 176.69 mm | 184.58 mm | 184.28 mm |
Runway (months of cash) | n/a | n/a | 12.6 | 15.6 | 18.2 | 18.1 |
Institutional ownership, Q2 2023
88.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 159 |
Opened positions | 47 |
Closed positions | 37 |
Increased positions | 60 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 1.46 tn |
Total shares | 82.67 mm |
Total puts | 581.80 k |
Total calls | 245.20 k |
Total put/call ratio | 2.4 |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 11.42 mm | $216.35 bn |
BLK Blackrock | 4.65 mm | $88.12 bn |
STT State Street | 4.64 mm | $87.99 bn |
JHG Janus Henderson | 4.12 mm | $78.04 bn |
Pictet Asset Management | 3.58 mm | $67.75 bn |
Biotechnology Value Fund L P | 3.52 mm | $0.00 |
Vanguard | 3.37 mm | $63.86 bn |
Holocene Advisors | 2.64 mm | $50.00 bn |
Suvretta Capital Management | 2.39 mm | $45.35 bn |
FHI Federated Hermes Inc - Ordinary Shares | 2.13 mm | $40.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Rohan Palekar | Common Stock | Sell | Dispose S | No | Yes | 10.91 | 52,718 | 575.15 k | 459,171 |
1 Apr 24 | Rohan Palekar | Common Stock | Option exercise | Acquire M | No | No | 1.93 | 25,000 | 48.25 k | 511,889 |
1 Apr 24 | Rohan Palekar | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.93 | 25,000 | 48.25 k | 120,231 |
26 Feb 24 | Rohan Palekar | Common Stock | Sell | Dispose S | No | Yes | 10.76 | 4,477 | 48.17 k | 486,889 |
17 Feb 24 | Ryan Martins | Common Stock | Payment of exercise | Dispose F | No | No | 9.74 | 778 | 7.58 k | 106,609 |
17 Feb 24 | Rohan Palekar | Common Stock | Payment of exercise | Dispose F | No | No | 9.74 | 4,602 | 44.82 k | 491,366 |
17 Feb 24 | Quoc Le-Nguyen | Common Stock | Payment of exercise | Dispose F | No | No | 9.74 | 1,046 | 10.19 k | 222,149 |
News
On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing
10 Apr 24
Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target
5 Apr 24
HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price Target
27 Mar 24
89bio Receives EMA PRIME Status For Pegozafermin In The Treatment Of Metabolic Dysfunction-Associated Steatohepatitis With Fibrosis And Compensated Cirrhosis
27 Mar 24
HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price Target
13 Mar 24
Press releases
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
17 Apr 24
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
27 Mar 24
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
89bio to Participate in the Leerink Partners Global Biopharma Conference
5 Mar 24